PD-1-targeted IL-2 variant antibody fusion protein RO7284755

{
  "id": "MLC-T-ONC-015881",
  "term": "PD-1-targeted IL-2 variant antibody fusion protein RO7284755",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant fusion protein comprised of an antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of PD-1-targeted IL-2v antibody fusion protein RO7284755, the antibody moiety specifically targets and binds to PD-1 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1-mediated downregulation of T-cell activation and proliferation. The IL-2 moiety may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T cells. This may enhance the activity of neoantigen specific T cells and potentiates T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T cells (Tregs).",
  "synonyms": [
    "PD-1-targeted IL-2v antibody fusion protein RO7284755",
    "PD-1-targeted IL2v cytokine RO7284755",
    "PD-1-targeted IL-2 variant immunocytokine RO7284755",
    "PD1-IL2v RO7284755"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pd-1-targeted-il-2-variant-antibody-fusion-protein-ro7284755/"
}